Volume 17, Number 3—March 2011
Dispatch
Laboratory-based Surveillance of Extensively Drug-Resistant Tuberculosis, China
Yunfeng Deng, Yan Wang, Junling Wang, Hui Jing, Chunbao Yu, Haiying Wang, Zhimin Liu, Edward A. Graviss, and Xin Ma
Table 1
First- and second-line drug resistance of 989 clinical Mycobacterium tuberculosis isolates, People’s Republic of China, November 2004–April 2007*
| Drugs* | No. isolates | Rate, % |
|---|---|---|
| Overall first-line drug resistance | 319 | 32.3 |
| INH | 187 (44) | 18.9 (4.4) |
| RFP | 159 (16) | 16.1 (1.6) |
| EMB | 46 (0) | 4.7 (0) |
| SM |
238 (78) |
24.1 (7.9) |
| MDR, overall | 107 | 10.8 |
| INH + RFP | 16 | 1.6 |
| INH + RFP + EMB | 2 | 0.2 |
| INH + RFP + SM | 58 | 5.9 |
| INH + RFP + EMB + SM |
31 |
3.1 |
| Overall second-line drug resistance | 189 | 19.1 |
| FQ | 162 (103) | 16.4 (10.4) |
| AMK | 32 (0) | 3.2 (0) |
| CPM | 56 (14) | 5.7 (1.4) |
| PAS |
37 (6) |
3.7 (0.6) |
| Second-line drug polyresistance | 66 | 6.6 |
| FQ + AMK | 8 | 0.8 |
| FQ + AMK + CPM | 9 | 0.9 |
| FQ + AMK + PAS | 4 | 0.4 |
| FQ + AMK + CPM + PAS | 6 | 0.6 |
| FQ + CPM | 15 | 1.5 |
| FQ + PAS | 10 | 1.0 |
| FQ + CPM + PAS | 7 | 0.7 |
| AMK + CPM | 3 | 0.3 |
| AMK + PAS | 1 | 0.1 |
| AMK + CPM + PAS | 1 | 0.1 |
| CPM + PAS | 2 | 0.2 |
*Numbers and rates of mono–first- and -second–line drug-resistant strains shown in parentheses. INH, isoniazid; RFP, rifampin;, EMB, ethambutol; SM, streptomycin; MDR, multidrug-resistant; FQ, fluoroquinolines (specifically ciprofloxacin and levofloxacin); AMK, amikacin; CPM, capreomycin; PAS, para-aminosalicylic acid.
Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.